Hisamitsu Pharmaceutical Co (FSE:4530) YoY EBITDA Growth: -11.90% (As of Nov. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FSE:4530 Hisamitsu Pharmaceutical Co Inc FSE:4530
89 GF Score
Price 円3,975.00
GF Value 円3,237.07
View Full Analysis

What is Hisamitsu Pharmaceutical Co YoY EBITDA Growth?

Hisamitsu Pharmaceutical Co FSE:4530 89 YoY EBITDA Growth is -11.90% as of Nov. 2025. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Hisamitsu Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Nov. 2025 was -11.90%.

Hisamitsu Pharmaceutical Co's EBITDA per Share for the three months ended in Nov. 2025 was 円39.58.

Hisamitsu Pharmaceutical Co YoY EBITDA Growth Related Terms

Hisamitsu Pharmaceutical Co YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co YoY EBITDA Growth Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.87 24.74 19.25 50.38 -9.53

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 535.08 -43.70 59.39 -11.90 -5.23
FSE:4530
89GF Score
Hisamitsu Pharmaceutical Co Inc FSE:4530
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Hisamitsu Pharmaceutical Co's YoY EBITDA Growth for the fiscal year that ended in Feb. 2026 is calculated as:

YoY EBITDA Growth (A: Feb. 2026 )
=(EBITDA per Share (A: Feb. 2026 )-EBITDA per Share (A: Feb. 2025 ))/ | EBITDA per Share (A: Feb. 2025 ) |
=(430.708-476.064)/ | 476.064 |
=-9.53 %

Hisamitsu Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Nov. 2025 is calculated as:

YoY EBITDA Growth (Q: Nov. 2025 )
=(EBITDA per Share (Q: Nov. 2025 )-EBITDA per Share (Q: Nov. 2024 )) / | EBITDA per Share (Q: Nov. 2024 )) |
=(39.575-44.918)/ | 44.918 |
=-11.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -11.90% mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a YoY EBITDA Growth of -11.90% as of Nov. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's YoY EBITDA Growth too high?
Hisamitsu Pharmaceutical Co's current YoY EBITDA Growth is -11.90%. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's YoY EBITDA Growth compare to AMPH and ESPR?
Hisamitsu Pharmaceutical Co's YoY EBITDA Growth of -11.90% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current YoY EBITDA Growth is -11.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current YoY EBITDA Growth of -11.90%. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current YoY EBITDA Growth is -11.90%. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current YoY EBITDA Growth is -11.90% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.

Key valuation signals for FSE:4530:

  • YoY EBITDA Growth: -11.90%
  • GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
  • GF Score™: 89/100

No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hisamitsu Pharmaceutical Co Business Description

Other Exchanges HTSUY:USA
Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score

Get the complete analysis for FSE:4530

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,975.00
Price
円3,237.07
GF Value